Supernus Pharmaceuticals (SUPN) Receives Daily News Sentiment Rating of 0.08

Media headlines about Supernus Pharmaceuticals (NASDAQ:SUPN) have been trending somewhat positive on Friday, according to Accern. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Supernus Pharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 46.3242332110571 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:

SUPN has been the topic of a number of recent research reports. BidaskClub raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, March 21st. ValuEngine raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 12th. Stifel Nicolaus lifted their price target on shares of Supernus Pharmaceuticals from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, May 25th. Finally, Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. Supernus Pharmaceuticals currently has an average rating of “Buy” and an average price target of $52.55.

Shares of NASDAQ:SUPN opened at $58.35 on Friday. Supernus Pharmaceuticals has a 12 month low of $33.30 and a 12 month high of $61.10. The company has a current ratio of 4.90, a quick ratio of 4.74 and a debt-to-equity ratio of 0.90. The firm has a market cap of $3.01 billion, a P/E ratio of 46.31 and a beta of 1.10.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Tuesday, May 8th. The specialty pharmaceutical company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.16. Supernus Pharmaceuticals had a net margin of 21.89% and a return on equity of 30.18%. The business had revenue of $90.43 million for the quarter, compared to analyst estimates of $85.26 million. During the same period last year, the business posted $0.19 earnings per share. The firm’s quarterly revenue was up 57.1% on a year-over-year basis. research analysts predict that Supernus Pharmaceuticals will post 1.9 earnings per share for the current fiscal year.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 7,868 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, May 15th. The shares were sold at an average price of $57.93, for a total value of $455,793.24. Following the sale, the vice president now directly owns 7,868 shares in the company, valued at approximately $455,793.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Stefan K.F. Schwabe sold 60,000 shares of Supernus Pharmaceuticals stock in a transaction on Monday, June 18th. The shares were sold at an average price of $54.39, for a total transaction of $3,263,400.00. Following the completion of the sale, the vice president now owns 21,967 shares in the company, valued at $1,194,785.13. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 212,850 shares of company stock worth $10,859,924. 6.20% of the stock is currently owned by company insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply